
Oral semaglutide did not slow Alzheimer's progression in EVOKE phase 3 trials
MedPage Today reports that Novo Nordisk announced the EVOKE phase III trials of oral semaglutide found no slowing of Alzheimer's disease progression. The post is a brief news share.


